Synthesize new molecules capable of reducing the invasiveness of glioblastoma (the most aggressive of brain tumors) and counteracting the phenomena of drug resistance to the chemotherapy currently in use. This is the goal pursued by a multidisciplinary and inter-university research team coordinated by the ENU member Dr. Gabriella Nicolini. The team includes biologists, biotechnologists and biochemists from the University of Milan-Bicocca ( professor Francesca Re and Dr. Alessio Malacrida of the Department of Medicine and Surgery) and chemists-pharmaceuticals of the University of Parma (Professor Valentina Zuliani and Professor Mirko Rivara of the Department of Food and Drug Sciences). The project entitled “Multidisciplinary approach to optimize the promising anti glioblastoma candidate MV1035”.
Supporting this research is the Celeghin Foundation, named after Giovanni Celeghin, a Paduan entrepreneur who died in 2011 from a multiform glioblastoma. The Foundation, which funds research on brain tumors, has allocated 100 thousand euros for the project conducted by Milan-Bicocca and Parma. In recent days, the president Annalisa Celeghin met Dr. Gabriella Nicolini and the pro-rector of Research of Milano-Bicocca, professor Guido Cavaletti, for the symbolic delivery of the funding.
Read more here https://bnews.unimib.it/blog/glioblastoma-la-fondazione-celeghin-finanzia-la-ricerca-di-milano-bicocca/ and listen to the interview realeased by Gabriella Nicolini and Guido Cavaletti here https://youtu.be/MmxdM-rCA3E (contents in italian olny)